Csk controls leukocyte extravasation via local regulation of Src family kinases and cortactin signaling.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
    • Publication Information:
      Original Publication: [Lausanne : Frontiers Research Foundation]
    • Subject Terms:
      Cortactin*/metabolism ; Cortactin*/genetics ; Signal Transduction* ; Cadherins*/metabolism ; Leukocytes*/metabolism ; Leukocytes*/immunology ; CSK Tyrosine-Protein Kinase*/metabolism ; Antigens, CD*/metabolism ; Antigens, CD*/genetics; Animals ; Humans ; Phosphorylation ; Mice ; Transendothelial and Transepithelial Migration ; Cell Adhesion ; Intercellular Adhesion Molecule-1/metabolism ; src-Family Kinases/metabolism ; Neutrophils/immunology ; Neutrophils/metabolism ; Endothelial Cells/metabolism ; Human Umbilical Vein Endothelial Cells ; Mice, Knockout
    • Abstract:
      C-terminal Src kinase (Csk) targets Src family kinases (SFKs) and thereby inactivates them. We have previously shown that Csk binds to phosphorylated tyrosine 685 of VE-cadherin, an adhesion molecule of major importance for the regulation of endothelial junctions. This tyrosine residue is an SFK target, and its mutation (VE-cadherin-Y685F) inhibits the induction of vascular permeability in various inflammation models. Nevertheless, surprisingly, it increases leukocyte extravasation. Here, we investigated whether endothelial Csk is involved in these effects. We found that the deficiency of Csk in endothelial cells augments SFK activation and the phosphorylation of VE-cadherin-Y685 but had no net effect on vascular leak formation. In contrast, the lack of endothelial Csk enhanced leukocyte adhesion and transmigration in vitro and in vivo. Furthermore, the silencing of Csk increased tyrosine phosphorylation of the SFK substrate cortactin. Importantly, the effects of Csk silencing on the increase in SFK activation, cortactin phosphorylation, and neutrophil diapedesis were all dependent on Y685 of VE-cadherin. Deletion of cortactin, in turn, erased the supporting effect of Csk silencing on leukocyte transmigration. We have previously shown that leukocyte transmigration is regulated by endothelial cortactin in an ICAM-1-dependent manner. In line with this, blocking of ICAM-1 erased the supporting effect of Csk silencing on leukocyte transmigration. Collectively, our results establish a negative feedback loop that depends on the phosphorylation of VE-cadherin-Y685, which recruits Csk, which in turn dampens the activation of SFK and cortactin and thereby the clustering of ICAM-1 and the extravasation of neutrophils.
      Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
      (Copyright © 2024 Stegmeyer, Holstein, Spring, Timmerman, Xia, Stasch, Möller, Nottebaum and Vestweber.)
    • References:
      J Vasc Res. 2003 Sep-Oct;40(5):435-41. (PMID: 14530600)
      Elife. 2021 Apr 28;10:. (PMID: 33908348)
      Cell. 1993 Jun 18;73(6):1117-24. (PMID: 7685657)
      Nat Cardiovasc Res. 2022 Dec 7;1(12):1156-1173. (PMID: 37936984)
      Oncogene. 2014 Sep 11;33(37):4537-47. (PMID: 24121272)
      Oncogene. 2007 Feb 15;26(7):1067-77. (PMID: 16909109)
      EMBO Rep. 2024 Sep;25(9):4013-4032. (PMID: 39112792)
      Annu Rev Pathol. 2011;6:323-44. (PMID: 21073340)
      Immunol Lett. 2004 Mar 29;92(1-2):43-9. (PMID: 15081526)
      Immunity. 2014 Nov 20;41(5):694-707. (PMID: 25517612)
      J Biol Chem. 2002 Mar 15;277(11):8771-4. (PMID: 11805080)
      Nature. 2000 Apr 27;404(6781):999-1003. (PMID: 10801129)
      Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3984-8. (PMID: 7513429)
      J Cell Biol. 2008 Nov 3;183(3):527-42. (PMID: 18955551)
      J Biol Chem. 2003 Feb 28;278(9):6936-41. (PMID: 12473651)
      J Biol Chem. 1999 Feb 26;274(9):5422-8. (PMID: 10026153)
      Blood. 2004 Feb 15;103(4):1370-2. (PMID: 14576066)
      J Exp Med. 2011 Aug 1;208(8):1721-35. (PMID: 21788407)
      J Cell Sci. 2008 Jan 1;121(Pt 1):29-37. (PMID: 18096689)
      J Biol Chem. 2010 Mar 5;285(10):7045-55. (PMID: 20048167)
      J Cell Biol. 2002 Jun 24;157(7):1233-45. (PMID: 12082081)
      EMBO J. 2011 Aug 19;30(20):4157-70. (PMID: 21857650)
      J Clin Invest. 2020 May 1;130(5):2301-2318. (PMID: 31971917)
      J Cell Sci. 2014 Oct 15;127(Pt 20):4470-82. (PMID: 25107367)
      Nat Rev Immunol. 2015 Nov;15(11):692-704. (PMID: 26471775)
      Nat Immunol. 2011 Jun 26;12(8):761-9. (PMID: 21706006)
      Front Cell Dev Biol. 2023 Jun 16;11:1206539. (PMID: 37397251)
      Am J Pathol. 1998 Jun;152(6):1463-76. (PMID: 9626051)
      J Exp Med. 2015 Dec 14;212(13):2267-87. (PMID: 26642851)
      J Cell Biol. 1993 Mar;120(6):1417-26. (PMID: 7680654)
      EMBO J. 2021 May 3;40(9):e106113. (PMID: 33604918)
      EMBO J. 2005 May 4;24(9):1686-95. (PMID: 15861137)
      J Exp Med. 2011 Nov 21;208(12):2393-401. (PMID: 22025303)
      Am J Physiol Heart Circ Physiol. 2014 Aug 1;307(3):H455-63. (PMID: 24858856)
      Trends Cell Biol. 2018 Feb;28(2):79-98. (PMID: 29162307)
      J Cell Sci. 1997 Mar;110 ( Pt 5):583-8. (PMID: 9092940)
      Nature. 1998 Aug 27;394(6696):901-4. (PMID: 9732874)
      J Exp Med. 2003 Nov 17;198(10):1453-62. (PMID: 14610046)
      Mol Cell. 1999 Dec;4(6):915-24. (PMID: 10635317)
      J Immunol. 2006 Nov 1;177(9):6440-9. (PMID: 17056576)
      J Immunol. 1985 Mar;134(3):1403-7. (PMID: 2981916)
      Nat Immunol. 2014 Mar;15(3):223-30. (PMID: 24487320)
      Nat Commun. 2012;3:1208. (PMID: 23169049)
      J Exp Med. 2006 Jul 10;203(7):1671-7. (PMID: 16818677)
      Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11933-8. (PMID: 17606906)
      Circ Res. 2006 Feb 17;98(3):394-402. (PMID: 16385081)
      J Exp Med. 2000 May 1;191(9):1591-604. (PMID: 10790433)
      Nat Rev Immunol. 2007 Sep;7(9):678-89. (PMID: 17717539)
      Cell. 1993 Jun 18;73(6):1125-35. (PMID: 8513497)
      Immunity. 2007 Jun;26(6):784-97. (PMID: 17570692)
      Mol Cell Biol. 1996 Sep;16(9):4765-72. (PMID: 8756634)
      Int J Biol Sci. 2012;8(10):1385-97. (PMID: 23139636)
      Cell Motil Cytoskeleton. 2008 Sep;65(9):687-707. (PMID: 18615630)
      J Cell Biol. 2004 Oct 25;167(2):377-88. (PMID: 15504916)
      Angiogenesis. 2005;8(4):315-26. (PMID: 16400523)
      Genesis. 2008 Feb;46(2):74-80. (PMID: 18257043)
    • Contributed Indexing:
      Keywords: Csk; ICAM-1; VE-cadherin; cortactin; endothelial cells; leukocyte extravasation
    • Accession Number:
      0 (Cortactin)
      0 (Cadherins)
      0 (cadherin 5)
      EC 2.7.10.2 (CSK Tyrosine-Protein Kinase)
      0 (Antigens, CD)
      126547-89-5 (Intercellular Adhesion Molecule-1)
      EC 2.7.10.2 (src-Family Kinases)
      EC 2.7.10.23 (CSK protein, human)
    • Publication Date:
      Date Created: 20241112 Date Completed: 20241112 Latest Revision: 20241114
    • Publication Date:
      20241115
    • Accession Number:
      PMC11550946
    • Accession Number:
      10.3389/fimmu.2024.1480152
    • Accession Number:
      39530094